Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | QPCT | Q16769 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15127609 | 0.90 | GSK3B (0.54) | GSK3BHRH3CA12CA1CA2 | |
| SCHEMBL2792585 | 0.86 | GSK3B (0.48) | GSK3BHRH3CA12CA1CA2 | |
| SCHEMBL3532271 | 0.78 | SPHK2 (0.74) | GSK3BQPCTVCPACHEMEN1 | |
| SCHEMBL17377392 | 0.78 | SPHK2 (0.74) | GSK3BQPCTVCPACHEMEN1 | |
| SCHEMBL13229677 | 0.77 | HRH3 (0.54) | GSK3BHRH3MAPTMEN1KMT2A | |
| SCHEMBL13262009 | 0.76 | GSK3B (0.59) | GSK3BHRH3CA12CA1CA2 | |
| SCHEMBL1344940 | 0.76 | TSHR (0.56) | GSK3BCA12CA1CA2CA9 | |
| SCHEMBL17377390 | 0.76 | GSK3B (1.00) | GSK3BQPCTMAPTACHEMEN1 | |
| SCHEMBL13229673 | 0.76 | HRH3 (0.56) | GSK3BHRH3CA12CA1CA2 | |
| SCHEMBL3541250 | 0.75 | GSK3B (0.45) | GSK3BHRH3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168190-A1 | Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) | YALE UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168190-A1 | Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) | OXA1L, POLRMT, PNP | GSK3B 1155/4885HRH3 2342/4885CA12 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.